Announcements Trials

Browse Landscape

Phase

Status

Recruiting 3 Active not recruiting 2 Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Cyclophosphamide 1495 Cisplatin 1431 Paclitaxel 1339 Radiotherapy 1308 Carboplatin 1264 Gemcitabine 1225 Docetaxel 1134 Bevacizumab 1068 Fluorouracil 906 Doxorubicin 799 Dexamethasone 753 Rituximab 744 Capecitabine 735 Oxaliplatin 709 pembrolizumab 693 Etoposide 674 Irinotecan 639 Filgrastim 624 Nivolumab 585 Cytarabine 585 Leucovorin 582 Vincristine 512 Cetuximab 478 Prednisone 477 Bortezomib 472 Trastuzumab 469 Erlotinib Hydrochloride 467 Surveys and Questionnaires 460 Methotrexate 443 Lenalidomide 434

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × copper dotatate CU-64 × Clear all

NCT02125474 2019-11-14

Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate

Instituto Nacional de Cancerologia, Columbia

Phase NA Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡